Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.

Green JB.

Postgrad Med. 2014 May;126(3):190-204. doi: 10.3810/pgm.2014.05.2767. Review.

PMID:
24918803
2.

Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.

Davidson MH.

Postgrad Med. 2014 May;126(3):56-65. doi: 10.3810/pgm.2014.05.2756. Review.

PMID:
24918792
3.

Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.

Ryan G.

Postgrad Med. 2015;127(8):842-54. doi: 10.1080/00325481.2015.1095616. Epub 2015 Oct 5. Review.

PMID:
26436470
4.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
5.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.

Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH.

Am J Cardiol. 2012 Sep 15;110(6):826-33. doi: 10.1016/j.amjcard.2012.04.061. Epub 2012 Jun 15.

PMID:
22703861
6.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008. Review.

7.
8.

DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

Bonora E, Cigolini M.

Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):273-84. doi: 10.1016/j.numecd.2016.03.002. Epub 2016 Mar 12. Review.

PMID:
27038847
9.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

10.

A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.

Basile JN.

Hosp Pract (1995). 2016;44(1):9-20. doi: 10.1080/21548331.2016.1141656. Epub 2016 Feb 2.

PMID:
26781810
11.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
12.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. Review.

13.

Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.

Azim S, Baker WL, White WB.

Curr Cardiol Rep. 2014 Nov;16(11):541. doi: 10.1007/s11886-014-0541-0. Review.

PMID:
25303895
14.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Cardiol. 2017 Jul 1;120(1S):S17-S27. doi: 10.1016/j.amjcard.2017.05.015. Epub 2017 May 30. Review.

15.

Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.

Coch RW, Green JB.

Nutr Metab Cardiovasc Dis. 2016 Sep;26(9):767-72. doi: 10.1016/j.numecd.2016.06.004. Epub 2016 Jun 16. Review.

PMID:
27378397
16.

Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.

Dokken B.

J Cardiovasc Nurs. 2016 May-Jun;31(3):274-83. doi: 10.1097/JCN.0000000000000245. Review.

PMID:
25829138
17.

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.

Blonde L.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S4-11. doi: 10.3949/ccjm.76.s5.02. Review.

PMID:
19952303
18.

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

Ovalle F.

Clin Ther. 2011 Apr;33(4):393-407. doi: 10.1016/j.clinthera.2011.04.006. Review.

PMID:
21635987
19.

Intensive glucose control and cardiovascular outcomes in type 2 diabetes.

Macisaac RJ, Jerums G.

Heart Lung Circ. 2011 Oct;20(10):647-54. doi: 10.1016/j.hlc.2010.07.013. Epub 2010 Aug 31. Review.

PMID:
20807681
20.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Cardiol. 2017 Jul 1;120(1S):S4-S16. doi: 10.1016/j.amjcard.2017.05.009. Epub 2017 May 30. Review.

Supplemental Content

Support Center